Combinatory ImmunoTherapy-1 (Com-IT-1) Irradiation and PD-1 Blockade in Locally Advanced / Advanced NSCLC

Inclusion Criteria: 5.1.1 Subject Inclusion Criteria * Age \>18 years * Advanced NSCLC * Adequate newly obtained core or excisional biopsy of a recurrent tumor lesion * Adequate is defined as a biopsy with at least 5 sections tumour tissue available. * Measurable disease according to RECIST criteria * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Life expectancy \> 3 months * A tumour lesion suitable for radiotherapy treatment * Adequate organ function based on clinical examination and lab values (Hb \>9.0, Leucocytes \> 2.0, Trc \> 100, AST/ALT \<3 ULN) * Women must not be pregnant or breastfeeding * WOCBP should use an adequate highly effective method to avoid pregnancy for 23 weeks * For the purpose of this document, a woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. * Highly effective contraception methods includes methods that can achieve a failure rate of less than 1% per year when used consistently and correctly. Such methods include: * combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal) * progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable) * intrauterine device (IUD) * intrauterine hormone-releasing system ( IUS) * bilateral tubal occlusion * vasectomised partner * sexual abstinence \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ * Males who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for a period of 90 days (duration of sperm turnover) plus the time required for the investigational drug to undergo five half-lives * Previously untreated or treated NSCLC pts, where treatment with PD1-inhibitor in indicated according to national guidelines. Exclusion Criteria: 5.1.2 Subject Exclusion Criteria * Disease suitable for curative salvage surgery * Treatment with any investigational medicinal product (IMP) that may interfere with the study treatment, within 2 weeks prior to first administration of study drug. * Significant cardiac, pulmonary or other medical illness that would limit activity or survival * Pregnancy or lactation. * Patients with EGFR-mutation or ALK-translocation not treated with tyrosine kinase inhibitor previously * Known hypersensitivity to any of the components of the investigational product * Patients who test positive for hepatitis B, C or HIV. * Known active brain metastases. Patients with stable / treated brain metastases can be included. * Diagnosis of immunodeficiency or medical condition requiring high doses (\>30 mg prednisolone daily) of systemic steroids or other forms of immunosuppressive therapy * Any reason why, in the opinion of the investigator, the patient should not participate